Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
Author:
Top Cited Papers
Open Access
- 4 February 2023
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 37 (3) , 255-265
Abstract
Rimegepant [Nurtec® ODT (USA); Vydura® (EU)] is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine with or without aura in adults, and for the preventive treatment of episodic migraine in adults. Rimegepant is available as an orally disintegrating tablet (ODT), which offers convenience and a potentially faster response time than the conventional tablet formulation. In pivotal phase III trials, rimegepant was more effective than placebo at relieving pain and the most bothersome symptom when taken as needed for the acute treatment of migraine. Rimegepant was also more effective than placebo at reducing the number of monthly migraine days when taken every other day for the preventive treatment of migraine. The beneficial effects of rimegepant in reducing migraine frequency and improving quality of life were maintained over the longer term (up to 52 weeks). Rimegepant was generally well tolerated, with no evidence of hepatotoxicity or cardiovascular toxicity in clinical trials. As the first dual agent approved for both treatment and prevention of migraine, rimegepant represents a useful option for the management of migraine in adults.Keywords
This publication has 55 references indexed in Scilit:
- Antagonism of CGRP Signaling by Rimegepant at Two ReceptorsFrontiers in Pharmacology, 2020
- Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptansPharmacology & Therapeutics, 2020
- PND76 LASMIDITAN, RIMEGEPANT AND UBROGEPANT FOR ACUTE TREATMENT OF MIGRAINE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSISValue in Health, 2020
- Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims DataJournal of Primary Care & Community Health, 2020
- Rimegepant oral disintegrating tablet for migraineThe Lancet, 2019
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trialThe Lancet, 2019
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for MigraineNew England Journal of Medicine, 2019
- Rimegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraineDrugs of the Future, 2019
- BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trialCephalalgia, 2013
- Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjectsThe Journal of Headache and Pain, 2013